Stock Track | DexCom Soars 5.32% in Pre-market on Strong Q1 Results and Analyst Upgrades

Stock Track
02 May

DexCom (DXCM) shares surged 5.32% in pre-market trading on Friday, following the company's impressive first-quarter results and a series of analyst upgrades. The medical device maker, known for its continuous glucose monitoring systems, reported better-than-expected sales and reaffirmed its full-year guidance, boosting investor confidence.

DexCom posted Q1 sales of $1.04 billion, surpassing analysts' estimates of $1.02 billion. The company reported a 14% organic revenue growth compared to Q1 2024, marking the second consecutive quarter of reaccelerating revenue growth. Despite supply chain challenges, DexCom successfully navigated short-term supply dynamics while maintaining strong demand in the US market.

Following the earnings release, several analysts raised their price targets for DexCom. Canaccord Genuity increased its target to $106 from $103, while Leerink Partners and Mizuho also raised their targets to $101 and $95, respectively. These upgrades reflect growing optimism about DexCom's market position and growth prospects.

The company's strong performance was attributed to its expanded commercial reach, leading to record levels of new customer starts, particularly from the type 2 non-insulin population. The introduction of Stelo, the first over-the-counter CGM, and broader coverage within the type 2 market have been well-received, enhancing customer experience. Additionally, DexCom announced a $750 million share repurchase program, signaling confidence in its strong revenue and cash flow growth outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10